Loading clinical trials...

Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo | Clinical Trials | Clareo Health

COMPLETED

Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo

Seroepidemiological Study of SARS-CoV-2 Infection in Population Subgroups in the State of São Paulo

NCT04408014•Butantan Institute

View on ClinicalTrials.gov

Summary

Seroepidemiological Study of SARS-CoV-2 Infection in Population Subgroups in the State of São Paulo

Detailed Description

This is a cross-sectional study to estimate the prevalence of antibodies against SARS-CoV-2 is different population subgroups in the State of São Paulo

Eligibility

Age

0 - 100 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•All potential volunteers invited to participate in the study.

Exclusion Criteria

•All potential eligible participants, but who do not show interest in participating in the study.

Locations (1)

Avenida Vital Brasil 1500

São Paulo, Brazil

Key Dates

Start Date

June 1, 2020

Primary Completion Date

July 15, 2020

Completion Date

July 30, 2020

Last Updated

February 15, 2024

Enrollment

18,901

ACTUAL participants

Conditions

COVIDSARS-CoV 2

Interventions

Serological test

DIAGNOSTIC_TEST

Nasopharyngeal Swab

DIAGNOSTIC_TEST

Oropharyngeal Swab

DIAGNOSTIC_TEST

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

NCT06082518

Post COVID-19 ConditionPost-COVID-19 Syndrome+4 more

View study

RECRUITINGPHASE1

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162

COVID-19

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 15, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo

Inclusion Criteria

Exclusion Criteria

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Taurine Supplementation in Long COVID

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Dime La VerDAD: Verify, Debunk, and Disseminate